Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB.

J Thorac Oncol. 2014 Jan;9(1):121-5. doi: 10.1097/JTO.0000000000000027.

PMID:
24346101
[PubMed - indexed for MEDLINE]
2.

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-85. doi: 10.1007/s00280-010-1265-5. Epub 2010 Feb 18.

PMID:
20165849
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.

Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):309-12. Chinese.

PMID:
16875636
[PubMed - indexed for MEDLINE]
4.

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.

Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM.

Lung Cancer. 2011 Dec;74(3):481-5. doi: 10.1016/j.lungcan.2011.05.005. Epub 2011 May 26.

PMID:
21620511
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.

Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Nishiwaki Y.

Cancer Chemother Pharmacol. 2003 Jul;52(1):19-24. Epub 2003 Apr 24.

PMID:
12712259
[PubMed - indexed for MEDLINE]
6.

A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.

Cobo M, Gutiérrez V, Alcaide J, Alés I, Villar E, Gil S, Durán G, Martínez J, Carabantes F, Bretón JJ, Benavides M.

Lung Cancer. 2007 May;56(2):255-62. Epub 2007 Feb 5.

PMID:
17276537
[PubMed - indexed for MEDLINE]
7.

Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.

Schneider BJ, Kalemkerian GP, Kraut MJ, Wozniak AJ, Worden FP, Smith DW, Chen W, Gadgeel SM.

J Thorac Oncol. 2008 Dec;3(12):1454-9. doi: 10.1097/JTO.0b013e31818de1d2.

PMID:
19057272
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.

Ishimoto O, Sugawara S, Inoue A, Ishida T, Munakata M, Koinumaru S, Hasegawa Y, Suzuki T, Miki H, Saijo Y, Nukiwa T.

J Thorac Oncol. 2006 Nov;1(9):979-83.

PMID:
17409982
[PubMed - indexed for MEDLINE]
9.

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.

Califano R, Griffiths R, Lorigan P, Ashcroft L, Taylor P, Burt P, Lee L, Chittalia A, Harris M, Faivre-Finn C, Thatcher N, Blackhall F.

Lung Cancer. 2011 Sep;73(3):338-44. doi: 10.1016/j.lungcan.2011.01.001. Epub 2011 Feb 5.

PMID:
21296449
[PubMed - indexed for MEDLINE]
10.

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

Rebattu P, Quantin X, Ardiet C, Morere JF, Azarian MR, Schuller-Lebeau MP, Pujol JL.

Lung Cancer. 2001 Aug-Sep;33(2-3):277-87.

PMID:
11551423
[PubMed - indexed for MEDLINE]
11.

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.

Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22. doi: 10.1007/s00280-010-1508-5. Epub 2010 Nov 11.

PMID:
21069335
[PubMed - indexed for MEDLINE]
12.

Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.

Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M.

Clin Transl Oncol. 2006 Oct;8(10):742-9.

PMID:
17074673
[PubMed - indexed for MEDLINE]
13.

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.

Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS.

Br J Cancer. 2012 Feb 28;106(5):839-45. doi: 10.1038/bjc.2012.21. Epub 2012 Feb 14.

PMID:
22333598
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA, Leopold L.

J Thorac Oncol. 2011 Apr;6(4):781-5. doi: 10.1097/JTO.0b013e31820a0ea6.

PMID:
21289522
[PubMed - indexed for MEDLINE]
15.

Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.

Chen YM, Shih JF, Lee CS, Chen MC, Lin WC, Tsai CM, Perng RP.

Lung Cancer. 2003 Feb;39(2):209-14.

PMID:
12581575
[PubMed - indexed for MEDLINE]
16.

Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.

Sangha R, Davies AM, Lara PN Jr, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR.

J Thorac Oncol. 2011 Dec;6(12):2112-9. doi: 10.1097/JTO.0b013e31822ae061.

PMID:
21892109
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.

Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH, Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, Nam SH, Kim BS.

Lung Cancer. 2010 May;68(2):248-52. doi: 10.1016/j.lungcan.2009.06.026. Epub 2009 Aug 3.

PMID:
19647333
[PubMed - indexed for MEDLINE]
18.

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, Dunn R, Hussain M.

Invest New Drugs. 2012 Feb;30(1):249-57. doi: 10.1007/s10637-010-9503-6. Epub 2010 Aug 5.

PMID:
20686817
[PubMed - indexed for MEDLINE]
19.

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.

Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP.

Int J Cancer. 2002 Mar 1;98(1):141-7.

PMID:
11857398
[PubMed - indexed for MEDLINE]
20.

Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.

Lara PN Jr, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR.

J Thorac Oncol. 2006 Feb;1(2):126-34.

PMID:
17409841
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk